股市必读：神州细胞（688520）12月26日主力资金净流出56.57万元

Core Viewpoint - Shenzhou Cell (688520) has received significant government subsidies and regulatory approval for a new indication of its product, which is expected to positively impact future revenue [1][3]. Trading Information Summary - On December 26, Shenzhou Cell closed at 44.22 yuan, down 0.74%, with a turnover rate of 0.54%, a trading volume of 24,000 shares, and a transaction amount of 106 million yuan [1]. - Main funds experienced a net outflow of 565,700 yuan, while speculative funds saw a net inflow of 2,428,900 yuan, and retail investors had a net outflow of 1,863,100 yuan [1][3]. Company Announcements Summary - Shenzhou Cell's subsidiary received two government subsidies totaling 95.27 million yuan, classified as revenue-related subsidies [1][3]. - The product, recombinant human coagulation factor VIII (brand name: Anjain), has received approval for a new indication for managing perioperative bleeding in patients with hemophilia A, marking it as the first domestically produced product in this category to gain such approval [1][3].